What does this research mean for the field?

Capmatinib can produce a marked systemic response in metastatic NSCLC with concurrent high PD-L1 expression and intermediate MET amplification, even when the MET copy number is below the threshold usually associated with benefit. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Evaluate the therapeutic challenges and optimal sequencing of targeted therapy versus immune checkpoint inhibition in metastatic non-small cell lung cancer harboring concurrent MET amplification and high PD-L1 expression.

August 30, 2026CureusOpen Access

Therapeutic Challenges in Metastatic Non-small Cell Lung Cancer (NSCLC) With Concurrent Mesenchymal-Epithelial Transition Factor (MET) Amplification and High Programmed Death-Ligand 1 (PD-L1) Expression: A Case Study

View Full Paper

Ask AI

Bookmark

Authors

MRMd. Arifur Rahman HSHasin Mesbah Bin Siddique MFMohammad S Faisal

Discussion

Member takes

Implication

Case report demonstrates marked response to capmatinib in metastatic NSCLC with intermediate MET amplification and high PD-L1 expression, highlighting complex treatment sequencing dilemmas.

Key Points

Evaluate the therapeutic challenges and optimal sequencing of targeted therapy versus immune checkpoint inhibition in metastatic non-small cell lung cancer harboring concurrent MET amplification and high PD-L1 expression.
Documented the clinical trajectory, treatment sequence, and response in a 65-year-old male presenting with metastatic lung adenocarcinoma.
Evaluated molecular markers via comprehensive genomic profiling (identifying intermediate MET amplification with copy number gain of 8 and TP53 mutation) and serial PD-L1 immunohistochemistry (22C3 TPS ~80% and SP142 TC 90%).
First-line platinum-doublet chemotherapy and second-line chemoimmunotherapy (atezolizumab plus carboplatin/pemetrexed) yielded transient mixed or partial responses before disease progression to the liver and brain.
Third-line targeted therapy with off-label capmatinib achieved a marked systemic response despite an intermediate MET copy number of 8 and the absence of a MET exon 14 skipping mutation.
Treatment was complicated by hepatic dysfunction and liver progression, leading to capmatinib discontinuation and patient death from liver failure and sepsis approximately 30 months after diagnosis.

Cite This Study

Rahman et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0696c1a8fb52e79c8aa https://doi.org/10.7759/cureus.115338

View Full Paper

Ask AI

Bookmark

Implication

Case report demonstrates marked response to capmatinib in metastatic NSCLC with intermediate MET amplification and high PD-L1 expression, highlighting complex treatment sequencing dilemmas.

Therapeutic Challenges in Metastatic Non-small Cell Lung Cancer (NSCLC) With Concurrent Mesenchymal-Epithelial Transition Factor (MET) Amplification and High Programmed Death-Ligand 1 (PD-L1) Expression: A Case Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Therapeutic Challenges in Metastatic Non-small Cell Lung Cancer (NSCLC) With Concurrent Mesenchymal-Epithelial Transition Factor (MET) Amplification and High Programmed Death-Ligand 1 (PD-L1) Expression: A Case Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider